GPGeneviève Plu-Bureau

Geneviève Plu-Bureau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Geneviève Plu-Bureau has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Vascular risk at menopause: The importance of a cardio-gynecological program

    by Iphigénie Cavadias, Sandrine Kretz, Chloé Kedziora, Claire Mounier-Vehier, Florence Trémollières, Geneviève Plu-Bureau


  • Approche spécifique du risque cardiovasculaire chez la femme

    by Manon Jouffroy, Geneviève Plu-Bureau, Claire Mounier-Vehier

    Chez la femme, le risque cardio-vasculaire est influencé par des facteurs différents de ceux reconnus pour la population masculine : facteurs hormonaux, complications obstétricales, maladies spécifiques comme la migraine, l’endométriose ou les maladies inflammatoires chroniques. Ces éléments modifient les risques artériel et veineux, qui, souvent, ne sont pas pris en compte par les scores classiques. Cette revue de la littérature met en avant ces déterminants féminins qui justifient du besoin d’outils de stratification, et d’une prévention personnalisée ainsi que d’une information renforcée tout au long de la vie.

  • Ménopause, traitement hormonal et risque cardiovasculaire

    by Geneviève Plu-Bureau, Iphigénie Cavadias, Brigitte Raccah-Tebeka, Manon Jouffroy, Claire Mounier-Vehier

    Chez la femme, les maladies cardiovasculaires représentent actuellement la deuxième cause de mortalité en France. La période de la ménopause constitue probablement le moment idéal pour dépister l’ensemble des facteurs de risque cardiovasculaires. Cette étape diagnostique est indispensable avant de proposer l’utilisation d’un traitement hormonal de la ménopause, s’il existe une véritable indication. Si ce traitement est autorisé, l’estradiol par voie transdermique associé à la progestérone naturelle constitue le traitement qui assure la meilleure sécurité d’emploi chez les femmes n’ayant pas d’antécédent d’hystérectomie. La tolérance de ce traitement, ainsi que l’ensemble des facteurs de risque cardiovasculaires, doivent être évalués annuellement afin d’optimiser la balance bénéfice-risque de ce traitement.

  • Open Access

    Risk of cardiovascular disease and mortality among women with endometriosis: A systematic review and meta‐analysis

    by Iphigénie Cavadias, Lorraine Maitrot‐Mantelet, Sandrine Perol, Mathilde Bourdon, Pietro Santulli, Louis Marcellin, Charles Chapron, Geneviève Plu‐Bureau

    Introduction: Endometriosis is a chronic and estrogen‐dependent disorder that affects about 10% of women of reproductive age worldwide. Endometriosis has been associated with chronic inflammation and an atherogenic lipid profile, two conditions that increase the risk of atherothrombotic cardiovascular diseases. Material and Methods: A literature search for relevant studies published from the earliest record to 31 March 2025 was conducted in MEDLINE and EMBASE databases. The following MESH terms were searched: “stroke,” “cerebrovascular disease,” “cardiovascular disease,” “coronary heart disease,” “ischemic heart disease,” “mortality,” and “endometriosis.” The results of each study were pooled, and an overall estimate of relative risk was obtained with a random‐effect model. Homogeneity between studies was analyzed using I 2 statistics. This review was not registered. Results: Ten studies were eligible for inclusion in this meta‐analysis. Five studies reported an increased risk of stroke with endometriosis, with a pooled risk of 1.18 (95% confidence intervals [95% CI] [1.13–1.22]). Four studies reported an increased risk of coronary heart disease with endometriosis, with a pooled risk of 1.36 (95% CI [1.32–1.40]). Four studies reported an increased risk of composite cardiovascular disease with endometriosis, with a pooled risk of 1.16 (95% CI [1.12–1.20]). Although the homogeneity is high in results, the confounding factors considered in the different studies vary. Thus, these results must be interpreted with caution. Conclusions: Endometriosis is associated with an increased risk of cardiovascular disease. Further research is required to confirm these findings. However, these results highlight the importance of considering primary cardiovascular prevention strategies for women with endometriosis.


  • Top Cited Papers
    Open Access

    Early Mortality, Cardiovascular, and Renal Diseases in Women's Lives Following Hypertensive Disorders of Pregnancy: The Prospective Nationwide Study CONCEPTION

    by Grégory Lailler, Clémence Grave, Amélie Gabet, Pierre Joly, Nolwenn Regnault, Catherine Deneux‐Tharaux, Vassilis Tstsaris, Geneviève Plu‐Bureau, Sandrine Kretz, Jacques Blacher, et al.

    Background: We aimed to evaluate the impact of hypertensive disorders of pregnancy occurrence, recurrence, onset time, and severity on mortality and on a wide range of cardiovascular outcomes in France. Methods and Results: CONCEPTION (Cohort of Cardiovascular Diseases in Pregnancy) is a French nationwide prospective cohort using data from the National Health Data System. We included all women in CONCEPTION with no history of a cardiovascular event who delivered in France for the first time between 2010 and 2018 (N=2 819 655). Hypertensive disorders of pregnancy and cardiovascular outcomes during the study follow‐up were identified using algorithms combining International Classification of Diseases, Tenth Revision ( ICD‐10 ) coded diagnoses during hospitalization and purchases of medication between 2010 and 2021. We fitted Cox models with time‐varying exposure to assess the associations of hypertensive disorders of pregnancy with mortality and cardiovascular events. Women with gestational hypertension had a 1.25‐ to 2‐fold higher risk of stroke, acute coronary syndrome, peripheral arterial disease, pulmonary embolism, and chronic kidney disease, and a 2‐ to 4‐fold higher risk of rhythm and conduction disorder and heart failure. Women with preeclampsia had a 1.35‐ to 2‐fold higher risk of rhythm or conduction disorder and pulmonary embolism during follow‐up; a 2‐ to 4‐fold higher risk of stroke, acute coronary syndrome, and peripheral arterial disease; and a 7‐ to 9‐fold higher risk of heart failure and chronic kidney disease. They were 1.8 times more likely to die and 4.4 times more likely to die of cardiovascular causes. Conclusions: Hypertensive disorders of pregnancy drastically increase the risk of mortality, cardiovascular, and renal events early after pregnancy. Recurrent, severe, and early‐onset preeclampsia further increases this risk.


  • NOBOX gene variants in premature ovarian insufficiency: ethnicity-dependent insights

    by Pénélope Jordan, Camille Verebi, Sandrine Perol, Sarah Grotto, Corinne Fouveaut, Sophie Christin-Maitre, Aude Brac de la Perrière, Virginie Grouthier, Sophie Jonard-Catteau, Philippe Touraine, et al.

    Purpose Premature ovarian insufficiency (POI) affects approximately 1% of women before the age of 40. Genetic contribution is a significant component of POI. The NOBOX gene was considered one of the major genetic causes of POI. However, the pathogenicity and the penetrance of NOBOX variants remain unclear. Methods We studied the whole coding region of the NOBOX gene by next generation sequencing in a cohort of 810 patients with POI, and we compared the frequency of each identified NOBOX variant to the general population taking into account the ethnicity of each individual. Results Screening of the whole coding region of the NOBOX gene allowed us to identify 35 different variants, including 5 loss-of-function variants. In total, 171 patients with POI (25%) carried out at least one NOBOX variant. Regarding missense variants, we observed a significant overrepresentation of the most frequent ones in our 810 POI patients as compared to the general, except for p.(Arg117Trp). However, taking into account the ethnic origin of the individuals, we observed no significant OR difference for p.(Arg44Leu) and p.(Arg117Trp) in African subgroup and for p.(Asp452Asn) in European subgroup. Conclusion This population study suggests that the p.(Arg44Leu) variant could be considered benign variant and that the p.(Asp452Asn) and p.(Arg117Trp) variants could be considered moderate risk pathogenic variants with probably partial and very low penetrance and/or expressivity. In contrast, p.(Gly91Trp) and p.(Gly152Arg) variants could be considered pathogenic variants with a moderate functional impact.


  • Approche et diagnostic de la maladie thromboembolique veineuse

    by Léonie Gey, Barbara Leclercq, Sarah El Harake, Pierre Suchon, Geneviève Plu-Bureau, Serge Cohen, Antoine Elias, Pierre Morange, Gabrielle Sarlon

  • Progestins and meningiomas

    by Geneviève Plu-Bureau